Prevention of Graves' ophthalmopathy.
Smoking is the most important risk factor for the occurrence/progression of Graves' ophthalmopathy (GO), as well as for its lower/slower response to immunosuppression. Accordingly, refrain from smoking should be urged, both as primary prevention (removal of risk factors in Graves' patients without GO), secondary prevention (early detection and treatment of asymptomatic/very mild GO) and tertiary prevention (reduction of complications/disability of overt GO). A 6-month course of 200 μg/day sodium selenite can prevent progression of mild GO to more severe GO and is, therefore, a form of secondary prevention and, probably, primary prevention. Correction of thyroid dysfunction and stable maintenance of euthyroidism are important preventive measures. The optimal treatment for hyperthyroidism in patients with GO is uncertain, because evidence demonstrating the superiority of antithyroid drugs over thyroid ablation (radioiodine, thyroidectomy, or both) is lacking. If radioiodine is used, low-dose steroid prophylaxis is recommended, particularly in smokers, to prevent radioiodine-associated GO progression.
Department of Clinical and Experimental Medicine, University of Insubria, Endocrine Unit, Ospedale di Circolo, viale Borri, 57, 21100 Varese, Italy. luigi.bartalena@uninsubria.it.
Luigi
L
Bartalena
D018450:Disease Progression; D042241:Early Diagnosis; D049970:Graves Ophthalmopathy / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery; D007037:Hypothyroidism / Q000188:drug therapy / Q000503:physiopathology; D012307:Risk Factors; D016540:Smoking Cessation